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Psoriasis today: experiences of healthcare 
and impact on quality of life in a major UK cohort 
 
Introduction 
 
In the UK and Northern Ireland it is estimated that up to 2% of the population have 
psoriasis (C.E.M. Griffiths & Barker, 2010), a visible and, for some, disabling, 
inflammatory skin disease (Bhosle, Kulkarni, Feldman, & Balkrishnan, 2006; Poulin 
et al., 2010; Wahl et al., 2006).  Surveys of people coping with long term conditions 
such as psoriasis can provide valuable insights and should lead to improvements in 
care.  They also establish a baseline against which any future improvements in 
experience can be measured and evaluated. While a large USA survey of psoriasis 
patients is now some 13 years old, surveys have been conducted more recently in 
Canada, France and Europe (Fouere, Adjadj, & Pawin, 2005; Krueger et al., 2001; 
Meyer et al., 2010; Poulin et al., 2010; Schmitt-Egenolf, 2006), and a recent UK 
study focussed on the psychosocial impact of psoriasis (Anstey, McAteer, Kamath, & 
Percival, 2012). These, and the more general psoriasis literature, document the 
difficulties experienced by those with this condition such as soreness, stigmatisation, 
difficult-to-manage treatment regimes, morbidity, associated co-morbidity, and a 
negative impact on their quality of life (Fouere et al., 2005; Gottlieb & Dann, 2009; 
Krueger et al., 2001; Langley, Krueger, & Griffiths, 2005; Meyer et al., 2010; Poulin 
et al., 2010).   
 
Interestingly, one of the European studies suggested that in the UK people with 
psoriasis (n = 246) were far more likely to rate their condition as ‘mild’ and to have 
treatments prescribed by their general practitioner when compared to their European 
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counterparts from Germany, France, Belgium and the Netherlands (Fouere et al., 
2005), suggesting that psoriasis is a condition which is often managed in primary 
care settings in the UK. The other, larger, European study did not include 
participants from the UK (Dubertret et al., 2006) and a direct comparison of self-
assessment of individuals’ psoriasis with the recent UK survey is difficult due to 
different terminology being used in the two studies: for example ‘very active’ may not 
equate to ‘severe’ (Anstey et al., 2012).   
 
While the recent UK study addressed psychosocial factors associated with psoriasis 
in some depth, there is a lack of recent research into the healthcare experiences of 
UK patients.  The following is a report on the findings from a postal, paper-based, 
survey which sought to remedy this and to assess and understand people’s 
experiences of diagnosis of psoriasis, their subsequent healthcare and treatments in 
the UK and the impact on daily life.  The discussion includes consideration of key 
areas for improvement in care. 
 
Material and Methods 
 
Materials 
 
A questionnaire was designed to gather demographic data and information on 
members’ experiences of diagnosis, quality of care, treatment, and healthcare 
professionals.  The design of the questionnaire was patient-association driven and 
focused on topics that arose regularly through the patient/members’ helpline.  In 
addition, a coping and quality of life section was included which drew on issues 
Psoriasis today: healthcare and quality of life 
4 
 
covered in the Dermatology Life Quality Index (DLQI) (Finlay & Khan, 1994).  
However, in this instance it was not, nor intended to be, a scale, but a series of 
discrete questions with a dichotomous response for the purpose of gathering data 
about the impact of psoriasis on specific aspects of daily life.   Participants could 
respond to two open questions in the survey with comments, but the data were 
predominantly quantitative.   Prior to circulation of the survey, minor amendments to 
the questionnaire were incorporated following invited patient feedback.  The 
research met the requirements of the Nursing, Midwifery and Social Work Ethics 
Committee at the University of Hertfordshire. 
 
Sample and Procedure 
 
Questionnaires, accompanied by an introductory letter and a reply-paid envelope, 
were sent out to all members of The Psoriasis Association (N = 2830) and 1619 were 
returned, giving a response rate of 57%.  Fifty-five of the returned questionnaires 
contained insufficient data to merit inclusion, making the final sample size N = 1564.  
Completion and return of the survey form were deemed consent to participate in the 
study and all data were entered anonymously into SPSS. 
 
Results 
 
Both sexes were equally represented as 751 (48%) participants were male.  Ages 
ranged from below 10 years to over 80 years old and were classified in age groups.  
Table 1 presents the distribution of the sample by group together with the mean 
length of time since participants’ diagnosis with psoriasis.  The mode age range of 
Psoriasis today: healthcare and quality of life 
5 
 
respondents was 61-70, representing 29% of the sample and the percentage of 
returned survey forms by age group was representative of the membership of The 
Psoriasis Association.   
 
The length of time that respondents had been affected by the condition ranged from 
1 month to 89 years.  Naturally their age group had a bearing on this and, while the 
overall mean length of coping with the condition was 32y 11m, analysis of this by 
age group indicates that the mean length of experience with psoriasis was 
approximately equal to half participants’ current lifespan. 
 
(Table 1 about here) 
 
Respondents experienced different types of psoriasis and sometimes more than one 
type.  Plaque psoriasis was the most common with 1265 (81%) participants reporting 
it.  Guttate psoriasis was reported by 211 (13.5%) respondents, while localised and 
generalised pustular psoriasis were the least frequently reported, with 89 (6%) and 
46 (3%) cases respectively. 
 
In terms of location, the scalp was the most commonly affected body area with 1160 
(74%) reporting it, followed by nails, 725 (46%), sensitive/flexural areas, 396 (25%), 
and the face, 375 (24%).  Additionally, 472 respondents reported having psoriatic 
arthritis, 337 of whom had received a formal diagnosis (representing 21% of whole 
sample).   Co-morbidity with psoriasis was common, with just under 70% reporting 
other conditions, such as hypertension, diabetes and osteoporosis. 
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Diagnosis and referral 
 
The majority (91%) of participants had approached their general practitioner (GP) for 
diagnosis in the first instance, with 25% already believing they had psoriasis.  The 
remainder sought the advice of a pharmacist (2%) or other health professional, 
including chiropodists and dermatologists.  Psoriasis was correctly diagnosed initially 
for 1180 (75%) participants.  However, 300 (19%) were given an incorrect initial 
diagnosis and responses on some survey forms suggested that reaching the correct 
diagnosis could be a lengthy process, exceeding a year in some instances.   
 
In total, 1027 (68%) of respondents were referred by their GP for specialist care and 
assessment, primarily to consultant dermatologists.  While 70% of those referrals 
were made on the initiative of the GP, some 298 (30%) participants requested 
referral by their GP.  Twenty-three participants (2%) were initially referred to hospital-
based dermatology specialist nurses; none were referred to dermatology specialist 
nurses in GPs’ surgeries.  Of those who attended secondary care, 27% went on, 
after specialist consultation, to be referred to the dermatology specialist nurse.  Only 
49% of those seen in secondary care were able to re-access the specialist 
dermatology department without re-referral from their GP if the condition flared.  Of 
the total sample, 465 (30%) had been admitted at some point for in-patient 
treatment, and two-thirds of these had been treated on a specialist ward.  Only 42 
respondents (2.6%) reported having in-patient treatment in the previous 12 months.  
 
Healthcare experiences 
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At the point of diagnosis, whether by a GP in primary or a specialist in secondary 
care, patients expressed some dissatisfaction with the information they received.  
Fifty-four per cent were not given adequate information about psoriasis and 56% 
were not given sufficient information about the treatments available.  Seventy-four 
percent reported that they were not offered different treatment options and many 
(54%) did not feel included in the decision-making process about their treatment.  
Forty-seven per cent would have welcomed more time, support and the opportunity 
to ask questions, and only 10% of participants were given contact details of support 
organisations. 
 
In terms of information and decisions about their prescribed treatment, 1137 (72.7%) 
of the respondents felt that they were given enough information about the treatments 
proposed for them in terms of application, how long it would take to work and 
potential side effects.  Only 64% felt that they had been given sufficient time to 
consider the choice of treatment.  Whilst these are both comparatively sizeable 
percentages, in a sample of this magnitude, it means that there is still a considerable 
number of participants who are less satisfied with the information received and the 
opportunity to make choices.   
 
Relationships with healthcare professionals were, nonetheless, largely positive.  
Participants only evaluated those health professionals with whom they came into 
regular contact and the following percentages relate to the sample size, given in 
brackets, responding about a specific professional.  Rating their relationships as 
either satisfactory or excellent with their GP (n = 1473) were 91% of respondents; 
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with their consultant dermatologist (n = 787), 87%; dermatology specialist nurse (n = 
360) 94%; and with their pharmacist (n = 772), 97%.   
 
Treatments and outcomes 
 
Table 2 presents details of treatments being used by survey participants at the time 
of the study.  Some patients were using up to nine different treatments, and topical 
treatments represented by far the largest category. 
 
(Table 2 about here) 
 
Respondents were asked about both the severity of their psoriasis and about their 
expectations of treatments.  Mild psoriasis was reported by 506 (32%), while 722 
(46%) respondents classified it as moderate, and 320 (21%) as severe.  Table 3 
gives mean ratings of how important participants perceive different outcomes of 
treatment.  With a minimum of 1 (not important) and a maximum of 4 (very 
important), mean scores over 3 signify ‘very important’.   
 
(Table 3 about here) 
 
Mean importance of treatment outcome scores were then assessed by severity 
group (mild, moderate, severe) and differences in mean were subject to analysis of 
variance.  These were found to differ significantly with p < .05, suggesting that those 
with more severely self-rated psoriasis rated the importance of treatment outcomes 
more highly.  Post hoc (LSD) analysis confirmed this.  However, no significant 
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differences in means were found between the groups rating their psoriasis as 
‘moderate’ or ‘severe’ for three options - clearance of visible areas, reduced redness 
and improvements to general wellbeing – indicating, perhaps, aspects of the 
condition that should be targeted for treatment in order to benefit most psoriasis 
patients. 
 
Psychosocial, practical and emotional impacts 
 
Respondents were asked to indicate how psoriasis had affected their daily life over 
the previous month and Figure 1 presents a frequency analysis of ‘yes’ responses. 
 
(Figure 1 about here) 
 
The main negative impacts of psoriasis were associated with coping with treatments, 
psychosocial functioning, and emotional distress.  However, the data also clearly 
indicated that despite 54% of respondents experiencing emotional distress, only 13% 
of those affected received professional help for it.  Negative effects on work, study 
and promotion were considerably lower, but may be influenced by the age group of 
the sample as 53% of participants were over the age of 60.  Indeed, age-related 
changes in the impact of psoriasis were found for other items (see Table 4) and 
suggest a lessening impact with age, particularly post-60y. 
 
(Table 4 about here) 
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A comprehensive analysis of the rich qualitative data produced by the survey 
exceeds the scope of this article; however, reference to representative comments by 
respondents support the above findings.  For example, topical treatments were 
perceived negatively by many patients. They were deemed sticky, messy, difficult 
and time-consuming, to the extent that they were viewed as ‘stressful’, ‘difficult to 
maintain’ and ‘a bigger nuisance than the condition’.  Moreover they were perceived 
by many to be ineffective.  On the other hand, there were favourable reports by 
some for the biological therapies.   Respondents indicated that GPs should be better 
informed, they wanted easier access to specialist dermatology clinics and greater 
innovation by the NHS with regard to psoriasis treatments.   
 
Comments related to psychosocial factors affirmed the pervasive effects of psoriasis 
on individual lives.  These ranged from the daily restrictions on clothing choices and 
no longer being able to swim or take part in sports, to the “embarrassment of itching 
and shedding scales at my desk”, and the severe negative impact on confidence, 
social lives, career choices and life paths.  Many acknowledged that stress was a 
trigger for flare-ups, and this was often associated with the practical limitations 
imposed by psoriasis or arising from the emotional distress which can accompany 
psoriasis at any age.   As one young woman wrote, 
“I feel very isolated living with psoriasis ... I feel like it is taking over 
my entire body day by day and has reduced my confidence to nil”.   
Another respondent reported that her young granddaughter told her, 
 “I’m not really frightened of you Granny, but I don’t like seeing your 
hands or feet”.   
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Men were equally affected by the condition and one explained that,  
“psoriasis now covers 75% of my body. I no longer swim.  I 
sunbathe when alone.  I have amicably separated from my wife as 
I am very sensitive about my condition.”   
Such findings, both quantitative and qualitative, indicate distressing aspects of the 
condition that do not currently appear to be adequately addressed. 
 
Discussion 
This survey presents a comprehensive assessment of the health experiences of 
people with psoriasis in the UK.  It also offers a further insight into the impact of 
psoriasis on everyday life.  The high response rate in this postal survey is, perhaps, 
indicative of some of the frustration experienced by psoriasis patients in relation to 
treatments which are currently available, and of the profound negative psychosocial 
impact and emotional distress associated with this long-term condition.  Self-
selection bias is a limitation of the study as participants were both members of the 
Psoriasis Association and prepared to complete the questionnaire.  However, a 
benefit of sampling through the Psoriasis Association is twofold: access to many who 
do not regularly attend primary or secondary care for their psoriasis, and information 
collected in an independent setting. 
 
In many respects the findings tend to support those of surveys from the international 
literature, including the older USA study (Krueger et al., 2001), particularly in relation 
to knowledge, psychosocial functioning, emotional distress and dissatisfaction with 
available treatments.  However, in this survey, when compared to the UK cohort in 
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the European study (Fouere et al., 2005), fewer Britons were likely to report their 
condition as ‘mild’.  This may be due, perhaps, to both the larger sample size in this 
study and to a far more equitable gender ratio (48% participants were male 
compared to only 36% in the UK cohort in the European study).   Respondents in 
this study were far less likely to report a negative impact of psoriasis on work and 
career than those in the Anstey et al. (2012) study and, again, context is an 
important consideration when comparing findings.  The Anstey et al. study was an 
online survey which had a sample with a much younger age bias – median age 
group 40-44y compared to the median age group of 61-70y in this postal survey.  
Indeed 7% respondents in this study were over the age of 80.  As might be 
expected, this is likely to affect responses to questions about work in the previous 
month.  However, such a comparison may also give some indication as to why some 
of the negative psychosocial impact of psoriasis appears to lessen with age 
(Unaeze, Nijsten, Murphy, Ravichandran, & Stern, 2006). 
  
The research provided an informative insight into the health and healthcare 
experiences of people with psoriasis and indicated a number of areas that merit 
further research or improvement.  For example, health policy in England and Wales 
favours the self-management of long-term conditions, regarding the patient as expert 
(Department of Health, 2011a, 2011b).  However, for this to be successful, and for 
patients to be able to properly manage their condition, it is essential that they are 
fully informed and involved in making choices about their treatment.  Yet, in common 
with other research findings (Poulin et al., 2010), respondents were aware of being 
under-informed, particularly by their GPs who, as their title suggests, do not have 
specialist knowledge of the condition nor of all available treatments.  Indeed the 
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qualitative data suggested that Psoriasis Association events and newsletters provide 
much-needed information that is not available to them elsewhere, and yet newly-
diagnosed patients were rarely given details of this or other skin disorder support 
organisations.  Moreover, the ability to re-access specialist dermatology services as 
necessary, as clearly recommended in a 2006 White Paper (Department of Health, 
2006b), was not apparent according to this research with only half of the 
respondents able to do this, thus restricting their access to current opinion and 
knowledge. 
 
The findings suggest scope for improving the training of primary care health 
professionals, both GPs and nurses, and for increasing the number of dermatology 
specialist nurses in primary care settings such as GP surgeries.  In particular, the 
latter could help to address needs identified here by providing appropriate care for 
those with straightforward, pre-diagnosed stable plaque psoriasis, promoting better 
patient knowledge and ensuring that support group details are provided to all 
patients diagnosed with psoriasis.  In this way changes at primary care level could 
help to improve patient care, optimise self-management and facilitate access and re-
access to secondary care for those with hard-to-manage psoriasis. 
 
In addition, current treatments frequently failed to meet patient needs and 
expectations.  Topical treatments were the most commonly prescribed and yet 
patients found them difficult, unpleasant and time-consuming to manage, and 
perceived them as ineffective. As the effectiveness of treatments can depend on 
adherence to correct usage (Ersser, Cowdell, Latter, & Healy, 2010), the difficulties 
that patients experience with them can render them ineffective, whether or not they 
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have the potential to be effective, and can hinder a successful outcome as far as 
self-management is concerned.  Patients need treatment appropriate to the severity 
of the condition (Poulin et al., 2010) and realistic treatment regimes from medications 
that, as indicated by the respondents in this survey, reduce the visible evidence of 
the condition and improve general wellbeing.  Certainly treatments that effectively 
improve visible appearance would have a positive consequence for wellbeing by 
allowing those with psoriasis a wider choice of clothing, and enabling them to be 
more socially active, thus promoting greater confidence.   In a similar vein this could 
also widen access to sporting activities, which is vital given the emerging evidence of 
a link between psoriasis and other co-morbidities such as cardiovascular disease 
(Gottlieb & Dann, 2009). 
 
The findings also highlight a fundamental aspect of psoriasis which continues to be 
overlooked by healthcare professionals and which, again, would contribute to 
general wellbeing: the lack of support for psychosocial functioning and emotional 
distress.  For example, the disparity between the high proportion of respondents 
experiencing psoriasis-related emotional distress (54%) and those receiving 
psychological support for it (only 13% of the 54%) clearly indicates a need which is 
currently not being met.  Moreover, strong similarities in responses to those found in 
the Anstey et al. (2012) study regarding emotional distress and confidence suggest 
that, unlike some of the psychosocial functioning aspects, the negative impact of 
psoriasis on mental health and emotional wellbeing does not lessen with time and 
age.  Evidence indicates that psychosocial and emotional support can be 
empowering, and can improve the condition and maintain those improvements by 
helping people to cope with stress and the daily hurdles imposed by psoriasis 
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(Fortune et al., 2002; C. E. M. Griffiths & Richards, 2001; Seng & Nee, 1997).  Given 
that stress is a known trigger for flare-ups, such support could prove crucial in 
helping to break the vicious circle.  However, it is also recognised that resistance by 
some patients to accepting ‘psychological’ help has been identified (Fortune et al., 
2002) and ways to overcome this may need to be researched and developed.  
 
Conclusions 
 
There were some encouraging findings in the survey in that relationships with 
healthcare professionals were, for most respondents, very positive and, concurring 
with other research (e.g. Unaeze et al., 2006), there appears to be a lessening 
impact on psychosocial functioning with age, and over time. The introduction and 
effectiveness of biological treatments were seen as positive, although they only 
benefitted 11% of respondents. However, aside from these factors, the experiences 
of respondents in this survey echo many of those in the 1998 US survey (Krueger et 
al., 2001) which suggests, disappointingly, that solutions to many of the problems 
associated with psoriasis have advanced little over the last thirteen years, despite 
continued research.   
 
The findings of this survey highlight that patients need to be better informed about 
the condition and treatments, both at diagnosis and over time, so that they are in a 
position to manage their condition effectively.  As suggested, improvements in 
training and resources at primary care level could help to achieve this. Secondly, 
topical treatments need to be developed further to become both manageable and 
effective, and to reflect the patient priorities, identified in the survey, of improving 
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visible appearance and promoting well-being. Finally, reports of the negative impact 
of psoriasis on psychosocial functioning and, in particular, the extent of emotional 
distress that is currently experienced underscore the urgent need to remedy the lack 
of formal social and psychological support mechanisms for those with psoriasis.  
These are key issues which, if addressed or further researched, could provide 
positive and tangible benefits for people coping with psoriasis. 
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